Cargando…

A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion

PURPOSE: The REal life assessmENt of safety And effeCTiveness of Razumab 2 (RE-ENACT 2) study evaluated the long-term effectiveness of biosimilar ranibizumab. We present the subgroup analysis of patients with retinal vein occlusion (RVO). METHODS: Data of patients who received pro re nata (PRN) bios...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Shashikant, Khan, Mujtaba, Chaturvedi, Alok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406620/ https://www.ncbi.nlm.nih.gov/pubmed/32617913 http://dx.doi.org/10.1007/s40123-020-00277-3

Ejemplares similares

A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World’s First Biosimilar Ranibizumab) in Wet Age-Related Macular Degeneration
por: Sharma, Shashikant, et al.
Publicado: (2019)

Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review
por: Sharma, Shashikant, et al.
Publicado: (2021)

Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
por: Chakraborty, Debdulal, et al.
Publicado: (2021)

Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study
por: Sharma, Shashikant, et al.
Publicado: (2021)

Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab
por: Verma, Lalit, et al.
Publicado: (2021)

Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study
por: Callizo, Josep, et al.
Publicado: (2019)

Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel
por: Gerding, Heinrich, et al.
Publicado: (2015)

Disease-modifying effects of ranibizumab for central retinal vein occlusion
por: Huang, Jason M., et al.
Publicado: (2021)

Real-world outcomes with ranibizumab in branch retinal vein occlusion: The prospective, global, LUMINOUS study
por: Pearce, Ian, et al.
Publicado: (2020)

Comparison of ranibizumab alone versus ranibizumab with targeted retinal laser for branch retinal vein occlusion with macular edema
por: Goel, Siddhi, et al.
Publicado: (2019)

Ranibizumab as an adjunct to laser for macular edema secondary to branch retinal vein occlusion
por: Azad, Rajvardhan, et al.
Publicado: (2012)

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion
por: Dogan, Emine, et al.
Publicado: (2018)

Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion
por: Unsal, Erkan, et al.
Publicado: (2015)

Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion
por: Gallego-Pinazo, Roberto, et al.
Publicado: (2012)

The use of bevacizumab and ranibizumab for branch retinal vein occlusion in medicare beneficiaries
por: Wu, Annie M., et al.
Publicado: (2018)

Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation
por: Ratra, Dhanashree, et al.
Publicado: (2021)

Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
por: Keane, Pearse A, et al.
Publicado: (2011)

Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion
por: Thom, Howard HZ, et al.
Publicado: (2014)

Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion
por: Son, Bo Kwon, et al.
Publicado: (2017)

Comparison of intravitreal ranibizumab monotherapy vs. ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion
por: Liang, Xuemei, et al.
Publicado: (2022)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Konidaris, Vasileios E., et al.
Publicado: (2018)

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
por: Rodríguez-Fernández, Carmen Antía, et al.
Publicado: (2022)

Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study
por: Lotery, Andrew, et al.
Publicado: (2021)

A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion
por: Bandello, Francesco, et al.
Publicado: (2018)

Alterations in Retinal Vessel Diameters in Patients with Retinal Vein Occlusion before and after Treatment with Intravitreal Ranibizumab
por: Aissopou, Evaggelia, et al.
Publicado: (2023)

Relationship between metamorphopsia and inner retinal microstructure following intravitreal ranibizumab injection for branch retinal vein occlusion
por: Sugiura, Yoshimi, et al.
Publicado: (2021)

Effects of Intravitreal Ranibizumab Injection on Peripheral Retinal Microcirculation and Cytokines in Branch Retinal Vein Occlusion with Macular Edema
por: Yasuda, Kanako, et al.
Publicado: (2023)

Comparing bevacizumab and ranibizumab for initial reduction of central macular thickness in patients with retinal vein occlusions
por: Singer, Michael A, et al.
Publicado: (2013)

Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA
por: Lotery, A J, et al.
Publicado: (2015)

Twelve-month outcomes in patients with retinal vein occlusion treated with low-frequency intravitreal ranibizumab
por: Sakanishi, Yoshihito, et al.
Publicado: (2016)

Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA
por: Nghiem-Buffet, S, et al.
Publicado: (2017)

Rapid formation of macular pucker following intravitreal ranibizumab injection for branch retinal vein occlusion
por: Oshiro, Ayano, et al.
Publicado: (2021)

Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective
por: Ni, Weiyi, et al.
Publicado: (2021)

Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema
por: Otawa, Taro, et al.
Publicado: (2022)

Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
por: Soman, Manoj, et al.
Publicado: (2022)

Retinal Microcirculation and Cytokines as Predictors for Recurrence of Macular Edema after Intravitreal Ranibizumab Injection in Branch Retinal Vein Occlusion
por: Noma, Hidetaka, et al.
Publicado: (2020)

Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy
por: McAllister, Ian L, et al.
Publicado: (2021)

Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2
por: Narayanan, Raja, et al.
Publicado: (2016)

Differentiation between Good and Low-Responders to Intravitreal Ranibizumab for Macular Edema Secondary to Retinal Vein Occlusion
por: Menke, Marcel N., et al.
Publicado: (2016)

Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure
por: Liu, Haiyang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_b22iacru2pac3b46bk9vj523j8